Loading viewer...
conference
Format: PDF conference
Clovis Oncology presented at the 35th Annual J.P. Morgan Healthcare Conference in January 2017, highlighting the December 2016 FDA approval of Rubraca (rucaparib), a PARP inhibitor for ovarian cancer. The presentation outlines the company's clinical development pipeline, including the ARIEL3 pivotal maintenance study expected to generate mid-2017 data, and discusses intellectual property protection through 2031-2035.
presentation
conference
29 Pages
Kardex
TETRA Technologies 2021 RBC Energy Conference Presentation
conferenceconference
30 Pages
TETRA Technologies, Inc.